Jun 06 2012
|more articles from|
Hikma Pharmaceuticals PLC Voting Rights and Capital
LONDON, 6 June 2012, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 May 2012 its capital consists of 196,822,407 ordinary shares with voting rights. There are no shares held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.
Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non ‐ branded generic and in ‐ licensed products. Hikma 's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.
Hikma Pharmaceuticals PLC
+44 20 7399 2760
NASDAQ Dubai is not responsible for the content of issuer disclosures. © 2009 NASDAQ Dubai. This e-mail and its attachments contain information which is confidential and may be legally privileged. It contains information on the NASDAQ Dubai Limited (NASDAQ Dubai) which is for the exclusive use of the intended recipient. If you are not the intended recipient(s), disclosing, copying, disseminating or otherwise taking any action in connection with this communication or the information in it is prohibited and may be unlawful. If you have received it in error, please notify the NASDAQ Dubai, delete it from your system, and destroy any copies.
© Copyright Zawya. All Rights Reserved.